1. Inhibitory Antibodies

Inhibitory Antibodies


MCE Inhibitory Antibodies are monoclonal antibodies (mAbs) that have been extensively used in the hottest research areas, such as cancer, immunology and infection. These monoclonal antibodies (mAbs) bind monospecifically to certain cells or proteins, thus stimulating the immune system to attack the malignant tumor cells and preventing tumor growth by blocking specific cell receptors. They can inhibit PD-1, PD-L1, EGFR, VEGFR, TNF-alpha or other targets which are unusually active in diseases, such as non-Hodgkin lymphoma, Hemophilia A, renal cell carcinoma, Parkinson's disease and metastatic HER2-positive breast cancer. For example, by binding to VEGF, Bevacizumab prevents VEGF from interacting with its receptors, thereby inhibiting new vessel growth. Lambrolizumab targets the programmed cell death 1 (PD-1) receptor of lymphocytes. By preventing the binding of its ligands (PD-L1 and PD-L2), Lambrolizumab induces an antitumor immune response.

Inhibitory Antibodies (675):

Cat. No. Product Name Purity
  • HY-P9907
    Trastuzumab 99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2.
  • HY-P9905
    Cetuximab 99.70%
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR.
  • HY-P9906
    Bevacizumab ≥99.0%
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-P9904
    Atezolizumab ≥98.0%
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-108841
    Raleukin ≥99.4%
    Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist.
  • HY-P9913
    Rituximab 99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9902
    Pembrolizumab 99.06%
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P9917
    Tocilizumab 99.67%
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling.
  • HY-P9970
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
  • HY-P9903
    Nivolumab 98.83%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-138298
    Trastuzumab deruxtecan (solution) 99.40%
    Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC).
  • HY-P9912
    Pertuzumab ≥99.10%
    Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-138298A
    Trastuzumab deruxtecan ≥99.0%
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC).
  • HY-P9908
    Adalimumab ≥98.0%
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9919
    Durvalumab 99.60%
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody[1].
  • HY-P9901
    Ipilimumab ≥99.0%
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells.
  • HY-108730
    Avelumab 99.30%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-P9926
    Dupilumab ≥99.2%
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis[1].
  • HY-108847
    Etanercept ≥98.0%
    Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor.
  • HY-P9910
    Obinutuzumab ≥99.4%
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.